. Metabolite sensing and signaling is not initiated by p-cresyl sulfate in CKD rats. (A) Indoxyl sulfate and (B) p-cresyl sulfate clearance in indoxyl sulfate or p-cresyl sulfate gavaged CKD rats. In line with indoxyl sulfate being a potent activator of the AhR-signaling pathway, clearance is induced upon indoxyl sulfate administration, whereas p-cresyl sulfate exposure merely results in clearance deterioration of both metabolites during the course of the experiment. (C) Representative images (red: OAT1, blue: nuclei) and (C') semi-quantification of OAT1 protein expression in control, indoxyl sulfate or p-cresyl sulfate CKD rat kidney slices. Data shown are mean ± S.E.M. Scale bar: 200 µm. Data shown are mean ± S.E.M. *= p<0.05, ***= p< 0.001. . Intracellular indoxyl sulfate is essential to increase OAT1 activity. Cells were incubated for 24h with indoxyl sulfate, probenecid or their combination, after which the fluorescein assay was performed in the presence or absence of probenecid to demonstrate active OAT1-mediated transport in the renal proximal tubule cells. After a 24 h incubation with indoxyl sulfate, a significant increase in OAT1 activity was observed, which was not observed in combination with probenecid. This indicates that uptake of indoxyl sulfate into proximal tubule cells is necessary to increase OAT1 activity. IS: indoxyl sulfate, Prob: probenecid. Data are shown as mean ± SD from four independent experiments. * = p<0.05, *** = p<0.001. Color code corresponds with figure 5A . Orange: p<0.05, yellow 0.10 >p > 0.05, white: not significant.
Supplementary methods
Clinical study I This is a secondary analysis of a previous randomised controlled trial exploring the influence of dietary protein intake on fecal water toxicity (clinicaltrials.gov NCT01280513 and Poesen et al. (21) ). Dietary interventions in healthy participants were conducted as described in detail by Poesen and co-workers. Briefly, healthy participants (n=12) were subjected to a 2-week high protein diet supplemented with 20 g protein powder per day (Resource, Nestlé Healthcare Nutrition, Switzerland; target of > 25% of total energy intake derived from protein intake), isocaloric to the habitual diet. Fiber and fat intake were maintained as constant as possible in each subject. At baseline and after the intervention period 48h urine was collected and stored at -80°C. Indoxyl sulfate concentrations were quantified using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method as described below.
To isolate urinary epithelial cells for OAT1 mRNA analysis, urine samples were centrifuged at 2000rpm for 10 min. The pellet was washed once using PBS and RNA was extracted using the RNAqueous micro total RNA isolation kit (ThermoFisher). Further processing including cDNA synthesis and qPCR analysis was performed as described in the gene expression analysis section.
Clinical study II
A number of 36 apparently healthy male and female subjects (ages 62 ± 8 years, BMI 25 ± 3 Kg/m2) entered a double blind, randomized, cross-over, trial. Subjects received three 1-week protein interventions (40 g/d protein concentrates from corn (Cargill, Belgium), bovine plasma (Darling ingredients/Sonac Loenen BV, the Netherlands) or whey (Danone research, the Netherlands)) with a 1-week washout period between interventions. 24-hours urine samples were collected before and after each intervention period. All samples were collected during a multi-sugar/acetylsalicylic acid test and a standardized evening meal prior to the study days. For the quantification of indoxyl sulfate and p-cresyl sulfate concentrations in the urine samples collected in clinical study II a LC-mass spectrometry (MS) method was used. Samples and aqueous calibration standards with indoxyl sulfate and p-cresyl sulfate were diluted 25 times with water, containing 13 C6-indoxyl sulfate and D7-p-cresyl sulfate as internal standards, and analyzed with the LC-MS system, consisting of a 1290 Infinity UHPLC and 6560 time-of-flight mass spectrometer (TOF-MS; Agilent Technologies, Waldbronn, BW, Germany). Separation was achieved using an Acquity UPLC HSS T3 column (100 x 2.1 mm, 1.8 μm particles), which was maintained at 40 °C during analysis. A 7.5-μL sample volume was injected into the system and the analytes were separated using gradient elution with 10 mM acetic acid (solvent A) and acetonitrile (solvent B) at a flow rate of 0.35 mL/min. An isocratic composition of 5% B was held for 1 min, followed by a linear increase to 15% B in 1 min, to 20% B in 2 min and to 100% B in 2.5 min. The LC system was coupled to the MS by a jet stream electrospray ionization source operated in negative polarity mode and using a nozzle voltage of 1000 V with a capillary voltage of 3500 V. The nebulizing gas and drying gas were nitrogen, with a nebulizing pressure of 40 psi and sheath gas flow rate of 11 L/min at a temperature of 350 °C. The drying gas temperature was 300 °C and had a flow rate of 8 L/min. Uremic toxins were identified and quantified using Masshunter software (Agilent Technologies).
Animal experiments
Animal experiments were approved by the University of Antwerp Ethics Committee (Permit number: 2012-13) and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals 85-23 (1996) . The animal experiment procedure is shown in Figure 1D . Animals were housed in pairs and exposed to a 12-hour light-dark cycle. To induce chronic kidney disease (CKD), 28 male Wistar rats (225-250g, Iffa Credo, Brussels, Belgium) were exposed to a 10-day adenine sulfate (Acros ® , Geel, Belgium) treatment via daily oral gavage (600 mg/kg/day). CKD rats were fed a phosphate-enriched diet (1.2% (w/v) Pi and 1.06 % (w/v) Ca) (SSNIFF Spezialdiäten, Soest, Germany) and randomly assigned to two treatment groups: (i) vehicle (n=14), (ii) 150 mg/kg indoxyl sulfate (Sigma-Aldrich) (n=14) and (iii) 150 mg/kg PCS (p-cresyl sulfate, department of Chemistry, Leuven, Belgium) (n=14). From the start of CKD induction onwards until week 2, both toxins were administered via the drinking water containing the solutes at a concentration corresponding to a daily intake of 150 mg/kg (56). After this period, vehicle, indoxyl sulfate or p-cresyl sulfate (150 mg/kg) were administered by daily oral gavage until sacrifice at week 7. Animals were placed in metabolic cages to collect 24h-urine followed by blood sampling at different time points; before the start of the study, at week 5 and at time of sacrifice. In addition, blood was sampled at week 3. At sacrifice, rats were exsanguinated through the retro-orbital plexus after anesthesia with sodium pentobarbital ((60 mg/kg) Nembutal, Ceva Santé Animale, France) via intraperitoneal injection. CKD and exposure to indoxyl sulfate and p-cresyl sulfate led to substantial mortality rates during the course of the study. Before the planned sacrifice, 4 vehicle, 6 indoxyl sulfate and 8 p-cresyl sulfate exposed CKD rats died. However, this did not compromise the study results as sufficient animals were included in the experiment. For the quantification of indoxyl sulfate and p-cresyl sulfate concentrations in the samples collected in clinical study I and in the in vivo experiment, we applied a liquid chromatography (LC)-tandem mass spectrometry (MS/MS) method as described by Poesen et al (21) . In short, aliquots of human and animal plasma were diluted in water, deproteinized with perchloric acid (final concentration 3.3% (v/v)) and supplemented with deuterated kynurenic acid as internal standard. Subsequent to centrifugation at 12,000 x g for 3 min, the supernatants were injected into an Accela LC system coupled to a TSQ Vantage triple quadropole mass spectrometer (Thermo Fischer Scientific, Breda, the Netherlands) with a C18 LC column (Acquity UPLC HSS T3 with 1.8 μm particles; Waters, Milford, MA, USA). The autosampler and column temperature were set to 8 °C and 40 °C, respectively, and the flow rate was set to 350 μL/min. For analysis, 10 uL of samples were injected three times, addressing (i) basic negative components, including indoxyl sulfate, (ii) acidic negative components, and (iii) acidic positive components, including kynurenic acid. For the first injection, the elution gradient went from 100% 10 mM NH4-acetate to 85% pure methanol over 7 min. For the second and third injection, the gradient went from 100% 5 mM ammonium acetate and 0.1% formic acid to 85% pure methanol in 7 min. The effluent from the LC was passed into the electrospray ion source and ionization was achieved using a nitrogen sheath gas with 2500 V for the negative and 3500 V for the positive electrospray ionization. MS/MS fragmentations and a selected reaction monitoring were performed. Indoxyl sulfate clearance was calculated according to equation 1:
[1] Cl = (Cu . Q) / Cp Cl = Clearance (ml/min) Cu = Urine concentration indoxyl sulfate (mmol/l) Q = Urine flow (ml/min) Cp = Plasma concentration indoxyl sulfate (mmol/l) In vitro assays AhR reporter and viability assay HG2L7.5c1 cells (human hepatoma (HepG2)-cell line) were stably transfected with a Ah receptorresponsive firefly luciferase reporter gene plasmid, pGudLuc7.5 (55). Cells were cultured in MEM alpha medium (Invitrogen, Thermo Fisher Scientific, Breda, The Netherlands) supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) Pen/Strep. The reporter assay was performed as described (55). Cell survival upon 24h uremic toxins exposure in HG2L7.5c1 cells was determined using a MTT viability assay. Cells were washed twice using PBS and incubated with 5 mg/ml MTT for 2 hours at 37°C. Next, cells were lysed in DMSO and absorbance (550-600 nm) was measured using a FLUOstar Omega plate reader (BMG labtechnologies, Isogen Life Science, De Meern, The Netherlands).
Gene expression profiling RNA was isolated from control or treated cells in the presence or absence of an AhR inhibitor alphanaphtoflavone (1 µM) using the PureLink RNA mini kit (Thermo Fisher Scientific) and cDNA was synthesised using the M-MLV reverse transcriptase kit, according to manufacturer's protocol. Using TaqMan primer probes mRNA expression levels were examined with gene arrays as listed in the key resources table. Gene expression levels were normalized to the reference gene GADPH and were expressed as fold change compared to control. The EGF signaling pathway was investigated using a RT2 cDNA synthesis first strand kit and Profiler gene array (PAHS-040Z; Qiagen Benelux B.V., Venlo, The Netherlands). In this array, five housekeeping genes were included (ACTB, B2M, GAPDH, HPRT1 and RPLP0) and gene expression levels were expressed as fold change compared to control. Data were plotted using Cytoscape software version 3.6.0.
Protein expression analysis
Nuclear ARNT (1:100 in protein block serum-free buffer (DAKO), C15A11, Cell Signaling) expression levels in ciPTEC monolayers were determined using the immunocytochemistry methodology as previously described (22) using a goat anti-rabbit IgG AlexaFluor 488 (1:200 in blocking buffer, Thermofisher). The high-content imager Yokogawa CV7000 and CellVoyager software were used to capture images and expression levels were quantified using ImageJ software. All experiments were performed in triplicate with at least 3 technical replicates per condition. Per replicate at least 20 nuclei were used for quantification, emphasizing that at least 180 nuclei per condition were used to perform statistical analysis. Data were normalized to control. OAT1 protein expression (1:100 dilution in 5% (w/v) milk-PBS-0.1% (v/v) tween blocking buffer, OAT11-A, Alpha Diagnostics Int) in cellular membrane fractions was determined using Western Blotting as described (22). Na,K-ATPase (1:2,000 in blocking buffer, C356-M09 (53)) was used as loading control, visualized using a goat anti-rabbit HRP (1:1,000 in blocking buffer, Abcam, Cambridge, UK) and the Amersham ECL Prime Western blotting detection reagent (VWR, Boxmeer, the Netherlands). Signal intensity was measured using the ChemiDoc MP system (Bio-Rad Laboratories BV, Veenendaal, the Netherlands) and Image Lab software version 5.2. Semi-quantification was performed using ImageJ software. Data were corrected for Na,K-ATPase (OAT1) expression levels and normalized to control. OAT1 protein expression in rat kidney slices was determined using immunohistochemistry. Paraffineembedded kidney slices were deparaffinized using xylol (2x 5 min), three times EtOH (70% (v/v)) wash, rinsed in MilliQ followed by Tris-EDTA antigen retrieval (VWR) by boiling 10 min. OAT1 antibody (PA1683, Boster Immunoleader, Pleasanton, CA) was diluted 1:100 in PBS-BSA (1% (v/v)) and incubated 2 hours at room temperature. Slices were washed three times using PBS and incubated using donkey anti-rabbit IgG AlexaFluor 568 (1:200 in PBS-BSA (1% (v/v)) for 2 hours at room temperature. After washing, slices were mounted using fluoromount-G plus dapi (Southern Biotech, Birmingham, AL) to stain nuclei. Images were captured using a Zeiss LSM880 microscope and signal intensity was quantified using ImageJ software. At least 10 tubules per kidney slice were analyzed. Data were background corrected and normalized to control.
Fluorescein transport in 2D
Fluorescein (1 µM) transport was investigated to evaluate transporter function in matured ciPTEC monolayers overexpressing OAT1, as described (27, 33) , using probenecid at 100 uM as positive control of transporter activity ( Figure S3 ). Cells were exposed to indoxyl sulfate (200 µM) in the presence or absence of AhR inhibitor (10 µM CH-223191), EGFR inhibitor (0.5 mg/ml Cetuximab, Merck Serono, Darmstadt, Germany), EGF (10 ng/ml), downstream EGF signalling inhibitors Bisindolylmaleimide (1 µM), U-0126 (2 µM, Cell Signaling Technology) , LY-942 (2 µM) and SN50 (10 µM), ROS scavengers Trolox (100 µM) or N-acetyl-L-cysteine (2 mM), scrambled-and antagomiR-223 for 24h (10 nM, VBC-Biotech, (48, 51)). The scrambled antagomiR contained 6 mismatches, all antagomirs were 3`cholesterol modificated, 2`O-methylated, and contained PTO linkages at the first two and last four nucleotides (58). Intracellular fluorescence (492 nm excitation, 518 nm emission) was measured using a Fluoroskan Ascent FL Spectrofotometer Labsystems (Thermo Fisher Scientific) plate reader. Blank fluorescence data were subtracted, and normalized data compared to control were plotted.
Transepithelial transport in 3D kidney tubules
Following exposure for 24h, either control or indoxyl sulfate (200 µM), kidney tubules (57) were perfused using a microfluidic system as described (33). Control and treated tubules were perfused (6 ml.h -1 ) with indoxyl sulfate (100 µM) for 10 min to allow transepithelial transport across the cell monolayer and apical samples were collected. The internal standard 13 C6-indoxyl sulfate was added and samples were analyzed using the same LC-MS method as described in the section 'Clinical study II'. Indoxyl sulfate concentrations measured in the standard solutions (dissolved in water) were used for sample quantification.
Reactive oxygen species generation analysis
To measure ROS, matured cells were loaded with 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, 10 µM, Thermo Fisher Scientific) for 20 minutes at 37°C, 5% (v/v) CO2. Next, the dye was removed, and monolayers were exposed to indoxyl sulfate in the presence or absence of a ROS scavenger, trolox (100 µM), for 24h. As a positive control, hydrogen peroxide (500 µM) was included. After 24h, intracellular fluorescence (485 nm excitation, 535 nm emission) was measured using a Fluoroskan Ascent FL Spectrofotometer Labsystems plate reader. Data were background corrected and the normalized intensity compared to control were plotted.
